- 14. Cash and cash equivalents
- 15. Trade accounts receivable
- 16. Inventories
- 17. Other current and non-current assets
- 18. Property, plant and equipment
- 19. Goodwill and other intangible assets
- 20. Accrued expenses
- 21. Other liabilities
- 22. Debt and capital lease obligations
- 23. Senior Notes
- 24. Mandatory Exchangeable Bonds
- 25. Trust preferred securities
- 26. Pensions and similar obligations
- 27. Noncontrolling interest
- 28. Fresenius SE & Co. KGaA shareholders’ equity
- 29. Other comprehensive income (loss)
16. Inventories
As of December 31, inventories consisted of the following:
| € in millions | 2012 | 2011 |
|---|---|---|
| Raw materials and purchased components | 433 | 385 |
| Work in process | 291 | 326 |
| Finished goods | 1,216 | 1,076 |
| less reserves | 100 | 70 |
| Inventories, net | 1,840 | 1,717 |
The companies of the Fresenius Group are obliged to purchase approximately €863 million of raw materials and purchased components under fixed terms, of which €552 million was committed at December 31, 2012 for 2013. The terms of these agreements run one to nine years. Advance payments from customers of €174 million (2011: €236 million) have been offset against inventories.
Inventories as of December 31, 2012 and December 31, 2011 included approximately €23 million and approximately €37 million, respectively, of the product Erythropoietin (EPO). On January 1, 2012, Fresenius Medical Care entered into a three-year sourcing and supply agreement with its EPO supplier. In the remaining two years, delays, stoppages, or interruptions in the supply of EPO could adversely affect the operating results of Fresenius Medical Care.
15. Trade accounts receivable
17. Other current and non-current assets